RZLT
HealthcareRezolute, Inc.
$1.97
$-0.20 (-9.24%)
Jan 5, 2026
Price History (1Y)
Analysis
Rezolute, Inc. is a biotechnology company in the healthcare sector with 75 employees and a market capitalization of $182.21M. The company's financial health is concerning, with net income of -$77,184,000, EBITDA of -$82,739,000, and free cash flow of -$41,905,248. The gross margin, operating margin, and profit margin are all 0.0%, indicating significant losses. The return on equity is -59.2% and the return on assets is -36.7%. Additionally, the company has a debt-to-equity ratio of 0.99, but its cash position is strong at $152.19M. The valuation context for Rezolute, Inc. includes a forward P/E ratio of -2.96, a price to book ratio of 1.22, and an EV/EBITDA of -0.60. The company's beta is 0.40.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $182.21M
- P/E Ratio
- N/A
- 52-Week High
- $11.46
- 52-Week Low
- $1.07
- Avg Volume
- 6.01M
- Beta
- 0.40
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 75